Bleselumab

• CAT Number: I042446
• CAS Number: 1453067-91-8
• Purity: ≥95%

Bleselumab (Cat No.: I042446) is a fully human monoclonal antibody that targets CD40, a co-stimulatory receptor expressed on antigen-presenting cells involved in immune activation. By blocking the CD40–CD154 interaction, Bleselumab suppresses T cell-mediated immune responses, making it a promising immunosuppressive agent for preventing transplant rejection and treating autoimmune diseases. It offers a non-depleting, selective approach to immune modulation, preserving overall immune function. Bleselumab is under investigation in clinical trials for kidney transplantation and other conditions requiring controlled immune regulation.

Reference

[1]. Harland RC, et al. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. Am J Transplant. 2020 Jan;20(1):159-171.
[Content Brief]

[2]. Okimura K, et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant. 2014 Jun;14(6):1290-9.
[Content Brief]

[3]. Song L, et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation. 2014 Aug 15;98(3):267-76.
[Content Brief]